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Objectives The purpose of this study was to examine temporal trends in post-percutaneous coronary intervention (PCI)
bleeding among patients with elective PCI, unstable angina (UA)/non–ST-segment elevation myocardial infarc-
tion (NSTEMI), and ST-segment elevation myocardial infarction (STEMI).
Background The impact of bleeding avoidance strategies on post-PCI bleeding rates over time is unknown.
Methods Using the CathPCI Registry, we examined temporal trends in post-PCI bleeding from 2005 to 2009 among pa-
tients with elective PCI (n  599,524), UA/NSTEMI (n  836,103), and STEMI (n  267,632). We quantified the
linear time trend in bleeding using 3 sequential logistic regression models: 1) clinical factors; 2) clinical  vas-
cular access strategies (femoral vs. radial, use of closure devices); and 3) clinical, vascular strategies  anti-
thrombotic treatments (anticoagulant  glycoprotein IIb/IIIa inhibitor [GPI]). Changes in the odds ratio for time
trend in bleeding were compared using bootstrapping and converted to risk ratio.
Results An approximate 20% reduction in post-PCI bleeding was seen (elective PCI: 1.4% to 1.1%; UA/NSTEMI: 2.3% to
1.8; STEMI: 4.9% to 4.5%). Radial approach remained low (3%), and closure device use increased marginally
from 44% to 49%. Bivalirudin use increased (17% to 30%), whereas any heparin  GPI decreased (41% to
28%). There was a significant 6% to 8% per year reduction in annual bleeding risk in UA/NSTEMI and elective PCI,
but not in STEMI. Antithrombotic strategies were associated with roughly half of the reduction in annual bleeding risk:
change in risk ratio from 7.5% to 4% for elective PCI, and 5.7% to 2.8% for UA/NSTEMI (both p 0.001).
Conclusions The nearly 20% reduction in post-PCI bleeding over time was largely due to temporal changes in antithrom-
botic strategies. Further reductions in bleeding complications may be possible as bleeding avoidance strate-
gies evolve, especially in STEMI. (J Am Coll Cardiol 2012;59:1861–9) © 2012 by the American College of
Cardiology Foundation
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Temporal Trends in PCI Bleeding Complications May 22, 2012:1861–9Bleeding complications after percu-
taneous coronary intervention (PCI)
are associated with increased mor-
bidity and mortality (1–5). The use
of bleeding avoidance strategies, in-
cluding safer approaches for vas-
cular access and hemostasis, and
selection of antithrombotic strat-
egies with improved safety profiles,
may reduce bleeding risk. Studies
have demonstrated that radial artery
access for catheterization is associ-
ated with fewer bleeding complica-
tions (6,7). Vascular closure devices
have the potential to decrease bleed-
ing complications in a select popu-
lation, although further trials are re-
quired to definitively test their benefit (8–11). Additionally,
randomized trials have demonstrated that an anticoagulation
strategy, such as the use of bivalirudin, in elective PCI, invasive
treatment of unstable angina (UA)/non–ST-segment elevation
myocardial infarction (NSTEMI), and primary PCI for ST-
segment elevation myocardial infarction (STEMI), has the
potential to reduce bleeding complications with similar
efficacy (12–14).
Despite the availability of this evidence, it remains
unclear to which extent these bleeding avoidance strategies
have been implemented in clinical practice, and subse-
quently led to measureable reductions in post-PCI bleeding.
Although a pooled analysis of 4 different Canadian registries of
NSTEMI patients demonstrated that bleeding rates did not
change from 1999 to 2008 (15), data from the overall
STEMI and STEMI population in the National Cardiovas-
ular Data Registry CathPCI Registry suggested a modest 19%
emporal reduction in post-PCI bleeding from 2.49% in 2005
o 2.01% in 2009 (16). To date, no study has investigated
hether temporal changes in bleeding avoidance strategies
ould help explain changes in bleeding rates.
Therefore, using the CathPCI Registry, we examined
hanges in post-PCI bleeding from 2005 to 2009 among 3
roups: 1) STEMI; 2) UA/NSTEMI; and 3) elective PCI, to
etermine whether or not the temporal reduction in post-PCI
leeding was significant. More importantly, we sought to
xamine the degree to which any temporal reduction in
ost-PCI bleeding was associated with temporal changes in
leeding avoidance strategies (vascular access strategies [radial
rtery catheterization and/or use of vascular closure devices]
nd/or choice of antithrombotic strategy).
ethods
he CathPCI Registry, a partnership between the Ameri-
an College of Cardiology and the Society for Cardiovas-
ular Angiography and Interventions, is a national quality
Abbreviations
and Acronyms
CHF  congestive heart
failure
GPI  glycoprotein IIb/IIIa
inhibitor
NSTEMI  non–ST-segment
elevation myocardial
infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
UA  unstable anginamprovement program that includes in-hospital data onpatients undergoing cardiac catheterization and PCI proce-
dures, and has been previously described (17,18).
Study population. The analysis utilized version 3 of the
CathPCI Registry, which contained data from 1,708,449
patient admissions for PCI from January 1, 2005, to June
30, 2009 at 1,031 sites. Patients who died on the day of their
PCI (n  5,125) or those with missing data on bleeding
(n  65) were excluded. Only index PCI procedures
performed during the study were included in this analysis.
Data definitions. Full description of the data elements in
version 3 of the CathPCI Registry (19). Major bleeding was
defined as: 1) bleeding requiring a blood transfusion or
prolonged hospitalization; 2) a decrease in hemoglobin
3.0 g/dl from any location, including percutaneous entry
site, retroperitoneal, gastrointestinal, genitourinary, and
other/unknown location; or 3) percutaneous entry site
hematoma 10 cm for femoral access, 2 cm for radial
access, or 5 cm for brachial access.
Estimated glomerular filtration rate was calculated using
the abbreviated modification of diet in renal disease formula
(20). The CathPCI Bleeding Model (2) includes the fol-
lowing variables: acute coronary syndrome type (STEMI,
UA/NSTEMI), cardiogenic shock, female gender, previous
congestive heart failure (CHF), no previous PCI, New York
Heart Association functional class IV CHF, peripheral
vascular disease, age, and glomerular filtration rate. Access
site bleeding was defined as any bleeding recorded as
bleeding at percutaneous entry site or retroperitoneal bleed-
ing if the patient had femoral artery catheterization or use of
an intra-aortic balloon pump. Nonaccess site bleeding was
defined as gastrointestinal bleeding, genital–urinary bleed-
ing, bleeding for any other cause, or spontaneous retroper-
itoneal bleeding (not related to catheterization or balloon
pump).
Abbreviated statistical analysis. Given that patients’ base-
line risk and procedurally associated risk of bleeding differed
according to indication for PCI, patients were initially
stratified into 3 groups by indication for PCI: 1) elective
PCI; 2) UA/NSTEMI; and 3) STEMI. Changes in patient
and procedural characteristics, and bleeding outcomes for
each subgroup were evaluated annually (from 2005 until the
second quarter of 2009). Continuous variables were de-
scribed as medians with 25th and 75th percentiles, whereas
categorical variables were expressed as frequencies with
percentages. The Kruskal-Wallis test was used to determine
whether there was any difference in continuous or ordinal
variables, whereas the Pearson chi-square tests were used to
determine any difference in categorical variables.
The primary endpoint of interest was major bleeding. To
determine whether the decreasing trend in bleeding over
time was significant, we added a linear time trend covariate
to the previously published CathPCI Bleeding Model (2)
for each of the 3 subgroups: Model 1, time (per unit year)
covariates in the CathPCI Bleeding Model.
We then added additional covariates to this model to
address the hypothesis that specific changes in practice
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p values for the comparison of adjusted odds ratios (ORs)
for time between models were obtained by bootstrapping.
Specifically, Model 2 is Model 1  vascular access strate-
gies. With respect to vascular access strategies, the data
collection form captured whether catheterization was per-
formed by radial artery access, femoral artery access, or if
closure devices were used. Sheath size, timing of sheath
removal, or duration of manual compression (which could
potentially influence bleeding rates) were not collected. To
the extent that vascular access strategies explain the tempo-
ral reduction in bleeding, we expected the adjusted OR for
time to attenuate toward 1 in Model 2 compared with
Model 1.
Similarly, Model 3 is Model 2 anticoagulation strategy.
Anticoagulation strategies were limited to 4 different strat-
egies: 1) heparin only; 2) bivalirudin only; 3) glycoprotein
IIb/IIIa inhibitor (GPI) plus heparin; and 4) bivalirudin
plus GPI. For the STEMI population, lytics were included
in the covariates of Model 3, because lytics are known to
influence the risk of bleeding (21–23). Bivalirudin was the
only direct thrombin inhibitor studied because it was the
predominant direct thrombin inhibitor used in99% of the
cases. Fondaparinux was not included as an anticoagulation
strategy, because it was used in 1% of the cases. Similar to
previously described techniques, controlling for anticoagu-
lation strategies would increase the OR for time toward 1 if
anticoagulation strategies meaningfully explained the trend
in bleeding rates.
We illustrated the differences between the subsequent
models in terms of changes in annual bleeding events. Using
the 2005 data as a reference population (observed bleeds:
n  1,375 bleeds in elective PCI; n  3,327 in UA/
NSTEMI; n  1,978 in STEMI), we calculated the
difference in predicted (expected) bleeding events obtained
by adding 1 year (time) to the 2005 patient cohort. For each
model, this provided the expected annual change, for a fixed
set of covariates. Given the complexity of the analysis, the
Online Appendix discusses a more elaborated statistical
plan.
Results
For each of the 3 groups, the patient demographics and
procedural characteristics during the first year (2005) and
the most recent year of data collection (first 2 quarters of
2009) are shown in Table 1 (Note: The table in the Online
Appendix demonstrates annual data during the study).
Patients in the STEMI group were more likely to be male
and have lower rates of previous myocardial infarction (MI),
CHF, diabetes, previous PCI or coronary artery bypass
grafting, and had higher use of an intra-aortic balloon pump
compared with the other 2 groups. Thrombolytics were
administered to 11.8% of the overall STEMI population,
although its use decreased annually from 17.4% in 2005 to
8.1% by 2009 (Online Appendix).Major bleeding over time. There was a modest 20%
temporal reduction in post-PCI bleeding overall (from 2.4%
in 2005 to 2.0% in 2009) and for each group (1.4% to 1.1%
in the elective PCI group, 2.3% to 1.8% in the UA/
NSTEMI group, and 4.9% to 4.5% in the STEMI group)
(Fig. 1). In comparison of access site versus nonaccess site
bleeding, there was a significant temporal reduction in
access site bleeding among all 3 groups (p 0.001) (Fig. 1).
Meanwhile, the annual rate of nonaccess site bleeding
remained relatively constant for elective PCI (p  0.104)
and UA/NSTEMI (p  0.827), and increased for the
STEMI group (from 2.6% to 3.1%) during the study
(p  0.001).
As demonstrated by Model 1 in Table 2, there was a
significant 6% to 8% per year reduction in risk of annual
bleeding among the elective PCI and UA/NSTEMI groups
after adjusting for clinical characteristics associated with
bleeding (i.e., covariates in the CathPCI Bleeding Model).
The largest relative annual reduction in risk was observed
for the elective PCI group (OR: 0.919; 95% confidence
interval [CI]: 0.895 to 0.945). Although there was a trend,
there was not a significant temporal reduction in annual
bleeding risk among the STEMI group (p  0.088).
Temporal changes in vascular access strategies and anti-
coagulation strategies. As seen in Figure 2, radial ap-
proach to catheterization was infrequent (1.5% overall).
Vascular closure device use was more common and in-
creased slightly during the study by a relative 10% to 13%
among all 3 groups (Fig. 3).
The changes in antithrombotic strategies over time were
much greater than that of vascular strategies (Fig. 4);
overall, bivalirudin use increased from 17% to 30%, whereas
heparin  GPI decreased from 41% to 28% during the
study. This was largely driven by the adoption of bivalirudin
only antithrombotic strategy in the elective PCI and UA/
NSTEMI groups, given that its use remained relatively low
(10%) in the STEMI group.
Association of changes in bleeding avoidance strategies
and outcomes: changes in vascular access strategies.
Model 2 was developed to assess whether the temporal
changes in vascular strategies could partly explain the
temporal reduction in annual bleeding events during the
study. As noted in Figure 5, after accounting for the vascular
strategies (Model 2), there was a small, but significant,
increase in the OR for time trend of annual bleeding toward
the null (i.e., 1) when comparing the adjusted OR of annual
bleeding estimated by Model 1 and Model 2 for the elective
PCI subgroup (OR: 0.920 to 0.924; p  0.001) and for the
UA/NSTEMI subgroup (OR: 0.939 to 0.942; p  0.015)
after accounting for vascular strategies (STEMI was not
reported because there was no temporal reduction in bleed-
ing for STEMI). This1% change in relative risk of annual
bleeding suggests that the temporal increase in vascular
access strategies (either radial artery access or use of vascular
closure devices) was associated minimally with the temporal
reduction in annual major bleeding rates.
i cardial
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and outcomes: changes in antithrombotic strategies.
Model 3 (Fig. 5) investigated the impact of the 4 different
anticoagulation strategies on the adjusted odds of in-
hospital major bleeding each year by comparing the adjusted
OR between Model 2 and Model 3. The odds of in-hospital
bleeding each year increased from 0.924 to 0.959 in the
elective PCI group (p  0.001) after adjusting for anti-
thrombotic use, translating to a reduction from 7.5% to 4%
annual relative risk of bleeding. For UA/NSTEMI, the OR
changed from 0.942 to 0.971 (p  0.001), translating to a
reduction from 5.7% to 2.8% annual relative risk of bleed-
ing. This suggests that either the increase in bivalirudin use,
the decrease in the use of heparin  GPI, or the combina-
tion of the 2 are associated with a larger portion of the
temporal reduction in post-PCI bleeding events. Conse-
Baseline, Clinical, and Procedural Characteristics Over TimeTable 1 Baseline, Clinical, and Procedural Characteristics Over
Elective PCI
2005
(n  98,194)
2009
(n  79,812)
Demographics
Age (yrs) 66 (57–74) 67 (58–75)
Male gender 66.8% 67.1%
Race
Caucasian 87.0% 79.4%
Black 5.4% 7.2%
Hispanic 2.4% 4.0%
Body mass index (kg/m2) 29.0 (25.7–33.1) 29.2 (25.8–33.4)
Previous MI (7 days) 27.4% 23.5%
Previous CHF 11.1% 11.8%
Diabetes 34.2% 37.0%
GFR (MDRD) 71.9 (57.5, 86.5) 72.8 (57.9, 88.2)
Cerebrovascular disease 11.8% 12.2%
Peripheral vascular disease 13.2% 13.6%
Hypertension 78.6% 83.5%
Former smoker 40.3% 38.4%
Current smoker 19.1% 18.8%
Smoker (former/current) 59.4% 57.2%
Dyslipidemia 77.1% 81.0%
Family history of CAD: age 55 yrs 29.4% 23.9%
Previous PCI 32.9% 30.3%
Previous CABG 20.2% 18.9%
Clinical presentation
CHF 7.9% 10.0%
Cardiogenic shock 0.5% 0.7%
Procedural characteristics
IABP 0.6% 0.7%
Multivessel disease 47.2% 47.3%
Multivessel PCI 15.6% 15.3%
Drug-eluting stent 85.8% 73.0%
Bare-metal stent 7.5% 20.4%
Post-procedure length of stay 2 (2, 2) 2 (2, 2)
Values are median (25th and 75th percentiles) or %.
CABG coronary artery bypass grafting; CAD coronary artery disease; CHF congestive hear
n Renal Disease formula; MI  myocardial infarction; NSTEMI  non–ST-segment elevation myo
infarction; UA  unstable angina.quently, anticoagulation strategies (Model 3) are associatedwith roughly 51% of the annual reduction in risk of annual
bleeding in UA/NSTEMI and roughly 47% reduction in
elective PCI.
Discussion
The present analysis of the CathPCI Registry found a
modest, but significant, decrease in the annual rate and risk
of in-hospital bleeding from 2005 to 2009 among elective
PCI and UA/NSTEMI patients who underwent PCI; there
was a temporal reduction in access site bleeding, suggesting
that this might have driven the reduction in overall bleed-
ing. We found that vascular access strategies did not change
much over this period, and thus, were minimally associated
with these observed reductions in bleeding rates over time.
In contrast, there was a marked temporal change in con-
e
UA/NSTEMI STEMI
2005
 144,633)
2009
(n  108,229)
2005
(n  40,369)
2009
(n  36,077)
4 (55–74) 65 (56–74) 59 (51–70) 60 (51–70)
64.7% 65.20% 71% 72%
87.2% 81.00% 86% 81%
5.9% 7.50% 5% 7%
2.2% 3.70% 3% 4%
.8 (25.5–33.0) 29.1 (25.7–33.3) 28.0 (25.0–31.8) 28.2 (25.1–32.1)
29.3% 25.80% 16.10% 14.60%
11.0% 11.30% 4.30% 4.10%
32.5% 35.20% 20.50% 22.30%
.8 (57.5, 88.2) 74.3 (58.4, 90.1) 74.1 (59.71, 89.4) 73.7 (59.4, 89.5)
12.2% 12.20% 6.50% 6.50%
12.2% 11.90% 5.9% 5.8%
76.8% 81.10% 58.2% 63.1%
35.8% 33.90% 22.7% 20.6%
27.3% 26.70% 44.6% 43.3%
63.0% 60.6% 67.4% 64.0%
74.7% 78.30% 56.40% 58.90%
29.4% 24.00% 25.80% 20.80%
32.2% 29.70% 13.90% 14.90%
21.1% 19.50% 5.50% 5.20%
9.3% 10.80% 9.10% 9.70%
1.1% 1.30% 8.60% 9.10%
1.5% 1.60% 9.60% 9.80%
52.3% 52.80% 52.90% 52.00%
15.6% 15.20% 7.2% 5.8%
85.7% 70.70% 78.80% 50.70%
7.9% 22.80% 13.90% 40.80%
2 (2, 3) 2 (2, 3) 4 (3, 5) 4 (3, 5)
; GFR glomerular filtration rate; IABP intra-aortic balloon pump; MDRDModification of Diet
infarction; PCI  percutaneous coronary intervention; STEMI  ST-segment elevation myocardialTim
(n
6
28
72
t failurecomitant antithrombotic strategy use during the study,
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May 22, 2012:1861–9 Temporal Trends in PCI Bleeding ComplicationsFigure 1 Bleeding Rates Among Elective PCI Population, UA/NSTEMI Population, and STEMI Population Over Time
(A) There was a significant temporal reduction for access-site bleeding, whereas there was no significant reduction in nonaccess site bleeding in the elective percutane-
ous coronary intervention (PCI) population. (B) There was a significant temporal reduction in access site bleeding for the unstable angina (UA)/non–ST-segment elevation
myocardial infarction (NSTEMI) population, whereas there was no significant reduction in nonaccess site bleeding. (C) There was a significant temporal reduction in
access site bleeding, and a significant temporal increase in nonaccess site bleeding. CI  confidence interval; OR  odds ratio.
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in risk of annual bleeding among elective PCI and UA/
NSTEMI.
Temporal trend in bleeding rates. In contrast to the study
by Elbarouni et al. (15), we found a significant temporal
reduction in bleeding rates. The contrasting conclusions
might be attributable to differences in treatment strategies,
different populations, study period, bleeding definition, and
patient sample size. Approximately half of the patients in
the Elbarouni et al. (15) analysis underwent cardiac cathe-
terization, and roughly half of these underwent subsequent
PCI. Meanwhile, our analysis was limited to PCI patients
only. Additionally, one-third of their data was collected
before 2003, during a time when GPI use was high (23).
Because the use of GPI is associated with higher bleeding
than heparin or bivalirudin alone, it is possible that high
rates of GPI use could help explain why these investigators
might not have noticed a reduction in bleeding over time.
Additionally, because our analysis included a later time
period, we were able to capture greater use of direct
thrombin inhibitors; as shown in the present analysis,
greater use of bivalirudin might explain some of the reduc-
tion in annual bleeding events. Other potential explanations
of the reduction in annual bleeding events include improve-
ments in reducing excess dosing during the study (24) and
greater attention to femoral access (25).
In our analysis, the largest relative reduction in annual
bleeding risks was noted to be in the elective PCI subgroup.
We did not find a significant temporal reduction in the
STEMI population, which might be because patients with
STEMI received more aggressive anticoagulation with
Temporal Reduction in Annual Bleeding RiskTable 2 Temporal Reduction in Annual Bleeding Risk
Group OR (95% CI) RR (95% CI) p Value
Elective PCI 0.920 (0.896–0.945) 0.921 (0.898–0.946) 0.001
UA/NSTEMI 0.939 (0.918–0.961) 0.941 (0.920–0.962) 0.001
STEMI 0.975 (0.948–1.004) 0.976 (0.952–1.005) 0.088
RR  risk ratio; other abbreviations as in Figure 1.
Figure 2 Rate of Radial Artery Catheterization Over Time
The radial approach for catheterization was used infrequently with only a slight
increase in use of radial approach over the study period. Abbreviations as in
Figure 1.dthrombolytics (11.8% of STEMI population) and had
greater use of intra-aortic balloon pumps (10% of STEMI
population), both of which are associated with increased
bleeding risk (26,27). The rate of bleeding in the STEMI
subgroup was more than twice that of the UA/NSTEMI
group and nearly 4 times that of the elective PCI group.
Potentially, increased use of bivalirudin might have reduced
bleeding rates in the STEMI group because previous data
showed improved bleeding outcomes in STEMI with use of
bivalirudin (14). Similarly, patients with STEMI had lower
rates of radial catheterization and closure device use, which
were associated (though minimally) with the temporal
reduction in bleeding in the elective PCI and UA/NSTEMI
groups. The increase in nonaccess site bleeding seen with
the STEMI group might have offset the benefit in access
site bleeding reduction over time. Further analysis to deter-
mine why nonaccess site bleeding in the STEMI group
trended up during the study is required, and a concerted
effort to develop and implement novel bleeding avoidance
strategies in the STEMI population is necessary. Greater
adoption of the radial approach to catheterization in
STEMI has the potential to reduce vascular complications
and potentially ischemic vascular events as seen in the recent
RIVAL (Radial Versus Femoral Access for Coronary Inter-
vention) trial (28).
Vascular access strategies. The present study also found a
small association between vascular access strategies to the
temporal reduction in bleeding. We may not have seen a
greater influence of the arterial access site given the infre-
quent use of radial catheterization; in the CathPCI data-
base, 1.5% of the overall population had their PCI via
adial access. It remains to be seen if greater adoption of
ransradial PCI in the United States alongside use of
ntithrombotics with improved safety profiles further affects
he temporal trends in bleeding rates, especially in the
TEMI population.
Given that the use of radial artery access was infrequent
nd did not change much over time, it is possible that the
elative 10% to 13% increase in closure device utilization
Figure 3 Vascular Closure Device Utilization Over Time
For each of the 3 groups, there was only a slight temporal increase in the use
of vascular closure device utilization over the study period. Abbreviations as in
Figure 1.uring the study accounted for the small, but significant,
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bleeding risk among the elective PCI and UA/NSTEMI
groups. The use of closure devices was recently shown to be
Figure 4
Changes in Utilization of Different Antithrombotic
Strategies Over Time: Elective PCI Population,
UA/NSTEMI Population, and STEMI Population
(A) The temporal increase in the use of procedural bivalirudin corresponded
with a reduction in the use of heparin  glycoprotein inhibitor (GPI). (B) The
temporal increase in the use of procedural bivalirudin corresponded with a
reduction in the use of heparin  GPI. The use of bivalirudin in UA/NSTEMI
was lower than that seen in the elective PCI population by the end of the study
period. (C) The use of heparin  GPI remained the predominant strategy for
PCI in the STEMI population. There was a slight increase in the use of bivaliru-
din toward the end of the study period. Abbreviations as in Figure 1.associated with lower bleeding in the CathPCI Registrypopulation (10) and the UA/NSTEMI population in the
ACUITY (Acute Catheterization and Urgent Intervention
Triage Strategy) trial (9). Of note, a meta-analysis suggested
that there might be no difference in bleeding comparing
closure devices with manual compression (29). Additionally,
greater attention by operators to minimize femoral access
complications (e.g., fluoroscopic guided puncture) might
have attenuated the impact of vascular access strategies.
Consequently, further trials looking at the use of closure
devices and other femoral access avoidance strategies to
reduce periprocedural bleeding are needed.
Anticoagulation strategies. As seen in Figure 4, the rates
of bivalirudin use increased linearly alongside a linear
decrease in the heparin  GPI strategy among the elective
PCI and UA/NSTEMI populations; however, the use of
bivalirudin remained infrequent among the STEMI popu-
lation by the end of the study (10% use of bivalirudin
alone). The 40% to 50% reduction in the risk of bleeding
each year after controlling for these antithrombotic strate-
gies suggests that either a temporal decrease in heparin 
GPI use and/or increase in bivalirudin use was associated
with the temporal reduction in bleeding rates. It remains to
be seen if a greater adoption of a bivalirudin strategy will
result in further improvements in bleeding outcomes, espe-
cially among the STEMI population, in which a random-
ized trial demonstrated similar efficacy with reduction in
bleeding using a bivalirudin strategy (14).
Moreover, it must be emphasized that changes in anti-
coagulation strategy only partly explain the decreasing trend
in bleeding. Unmeasured variables such as clinician bias in
selecting patients for intervention with lower complication
risk, bias in choice of vascular access strategy, bias in
selection of antithrombotic choice, improvements in anti-
thrombotic dosing, and greater physician awareness of
bleeding risk may also contribute to this decreasing tempo-
ral trend of bleeding. Further analysis of other populations
is necessary to duplicate these findings and investigate
whether changes in antithrombotic strategy contribute to
reduction in access site bleeding. Further investigation is
needed on minimizing nonaccess site bleeding.
Study limitations. First, the definition of bleeding used
was designed for a quality improvement registry. As a result,
bleeding was site-reported and not adjudicated, likely lead-
ing to an underestimate of actual bleeding rates. A more
comprehensive bleeding definition may have demonstrated
a greater annual reduction in bleeding. Second, it is possible
that patients with elective PCI may have been discharged
early, subsequently, underestimating in-hospital bleeding
rates. Similarly, length of stay may have influenced an
underestimation of in-hospital bleeding rates. Additionally,
the present analysis assumes that the difference between
Model 2 and Model 3 in each group is attributed to only
differences in bleeding due to antithrombotic strategies; it
assumes that all comorbidities that may influence choice of
medication have been captured in the regression model. As
with any retrospective analysis, there is selection bias in the
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statistical methods, there are likely unmeasured confound-
ers. The dataset version used for the present analysis did not
capture the use of prasugrel. Future analysis to determine
the influence of prasugrel on bleeding risk in a “real-world”
population is needed. Finally, we could not account for the
size of sheaths used, timing of sheath removal, or duration
of manual compression—all of which have the potential to
also reduce procedural bleeding. We could not determine
the effect of excess dosing of anticoagulants, nor antiplate-
lets, on bleeding outcomes with this registry.
To partially address these limitations, we accounted for
clustering of events (i.e., patients who underwent PCI at
specific centers were likely to be treated similarly) in our
analysis. Although the analysis demonstrated that the
changes in antithrombotic strategy over time helped explain
the temporal reduction in bleeding events, we were unable
to determine which specific change in antithrombotic ther-
apy (i.e., bivalirudin increase or heparin  GPI decrease)
ccounted for the change in bleeding events.
onclusions
he present analysis is the first paper to demonstrate a
ignificant temporal reduction in major bleeding over time
n the elective PCI and UA/NSTEMI population. This
emporal reduction was largely associated with changes in
rocedural antithrombotic strategy—either an increase in
ivalirudin use or a decrease in heparin  GPI. Meanwhile,
hanges in vascular access strategies had a smaller impact on
he change in bleeding risk, likely due to the extremely low
revalence of the radial approach and a small increase in the
se of vascular closure device utilization during the study.
Group OR (95% CI) 
Annual Risk 
Reducon in 
Bleeds* 
Elecve 
PCI 
0.920 
(0.896-0.945) 
7.9%/yr 
UA/NSTEMI
 
0.939 
(0.918-0.961) 
5.9%/yr 
Model 1 M
OR 
0
(0.90
0
(0.92
p<0.001
P=0.015
Vascular Access 
Strategies
• Model 1: Time + covariates in CathPCI Bleeding Mo
• Model 2: Model 1 + vascular access strategies  
• Model 3: Model 2 + ancoagulaon strategies  
 
*Risk reducon= (1-RR)*100 
Figure 5 Changes in Risk of Annual Bleeding After Accounting
Model 1 demonstrates annual risk reduction in bleeds after adjusting for time and
bleeding risk after further adjustment for vascular access strategies (Model 2). Fu
attenuation in annual bleeding thereby suggesting changes in anticoagulation stra
bleeding events.emporal bleeding in STEMI did not change significantly.t remains to be seen whether further changes in vascular
trategies—particularly increased adoption of transradial
CI, newer antithrombotics, or both—will further reduce
leeding rates, particularly in the STEMI population. Fu-
ure studies should continue to evaluate bleeding risk, as the
andscape of antithrombotic therapies and use of bleeding
voidance strategies continues to evolve.
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APPENDIX
For the elaborated statistical analysis,
please see the online version of this article.
